Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transdermal Drug Delivery Systems01:18

Transdermal Drug Delivery Systems

21
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
21
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

21
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
21
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

17
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
17
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

16
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
16
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

20
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
20
Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

23
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
23

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Humanization of an anti-human TNF-alpha antibody by variable region resurfacing with the aid of molecular modeling.

Molecular immunology·2005
Same author

[Expression of retinoic acid receptor-beta mRNA and p16, p53, Ki67 proteins in esophageal carcinoma and its precursor lesions].

Zhonghua zhong liu za zhi [Chinese journal of oncology]·2005
Same author

Atrial fibrillation in KCNE1-null mice.

Circulation research·2005
Same author

Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry.

Rapid communications in mass spectrometry : RCM·2005
Same author

[The clinical application of acellular dermal matrix to repair the defect of oral mucosa].

Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology·2005
Same author

Respiratory and cardiovascular actions of orexin-A in mice.

Neuroscience letters·2005

Related Experiment Video

Updated: Feb 15, 2026

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

814

Camptothecin-based nanodrug delivery systems.

Yan Wen1,2, Yingze Wang1, Xiaoli Liu1

  • 1CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Beijing 100190, China.

Cancer Biology & Medicine
|January 27, 2018
PubMed
Summary
This summary is machine-generated.

Camptothecin shows antitumor effects but faces challenges like toxicity and poor delivery. Nanotechnology offers a promising solution for developing improved camptothecin nanodrugs for cancer therapy.

Keywords:
Camptothecinscancer therapydrug delivery systemnanomedicine

More Related Videos

Development, Characterization, and Evaluation of CAGE-based Ionic Liquid Systems for Transdermal Delivery
09:44

Development, Characterization, and Evaluation of CAGE-based Ionic Liquid Systems for Transdermal Delivery

Published on: September 26, 2025

556
Models and Methods to Evaluate Transport of Drug Delivery Systems Across Cellular Barriers
18:57

Models and Methods to Evaluate Transport of Drug Delivery Systems Across Cellular Barriers

Published on: October 17, 2013

47.4K

Related Experiment Videos

Last Updated: Feb 15, 2026

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

814
Development, Characterization, and Evaluation of CAGE-based Ionic Liquid Systems for Transdermal Delivery
09:44

Development, Characterization, and Evaluation of CAGE-based Ionic Liquid Systems for Transdermal Delivery

Published on: September 26, 2025

556
Models and Methods to Evaluate Transport of Drug Delivery Systems Across Cellular Barriers
18:57

Models and Methods to Evaluate Transport of Drug Delivery Systems Across Cellular Barriers

Published on: October 17, 2013

47.4K

Area of Science:

  • Oncology
  • Nanotechnology
  • Drug Delivery

Background:

  • Camptothecin exhibits broad-spectrum antitumor activity against various cancers.
  • Camptothecin derivatives are crucial chemotherapeutic agents that inhibit topoisomerase 1 (Topo 1).
  • Conventional camptothecin drugs suffer from systemic toxicity, low tumor accumulation, poor bioavailability, and limited water solubility.

Purpose of the Study:

  • To review current advancements in camptothecin-based nanodrugs for cancer treatment.
  • To highlight nanotechnology as a strategy to overcome limitations of traditional camptothecin formulations.
  • To discuss potential applications of novel nanodrug delivery systems in clinical cancer therapy.

Main Methods:

  • Literature review of camptothecin-based nanodrugs.
  • Analysis of nanotechnology applications in overcoming drug delivery challenges.
  • Summary of current research hotspots in nanopharmaceutical preparations for cancer therapy.

Main Results:

  • Nanotechnology-based approaches are emerging as key strategies to enhance drug development.
  • Various camptothecin-based nanodrugs have been developed to improve therapeutic efficacy.
  • Nanodrug formulations show potential for increased drug accumulation at tumor sites and reduced systemic toxicity.

Conclusions:

  • Nanotechnology offers significant potential for developing improved camptothecin delivery systems.
  • Efficient nanodrug design can mitigate the limitations of conventional camptothecin chemotherapy.
  • Further research into nanopharmaceutical preparations could lead to more effective clinical cancer therapies.